Literature DB >> 24837749

Lysosomal storage diseases and the heat shock response: convergences and therapeutic opportunities.

Linda Ingemann1, Thomas Kirkegaard1.   

Abstract

Lysosomes play a vital role in the maintenance of cellular homeostasis through the recycling of cell constituents, a key metabolic function which is highly dependent on the correct function of the lysosomal hydrolases and membrane proteins, as well as correct membrane lipid stoichiometry and composition. The critical role of lysosomal functionality is evident from the severity of the diseases in which the primary lesion is a genetically defined loss-of-function of lysosomal hydrolases or membrane proteins. This group of diseases, known as lysosomal storage diseases (LSDs), number more than 50 and are associated with severe neurodegeneration, systemic disease, and early death, with only a handful of the diseases having a therapeutic option. Another key homeostatic system is the metabolic stress response or heat shock response (HSR), which is induced in response to a number of physiological and pathological stresses, such as protein misfolding and aggregation, endoplasmic reticulum stress, oxidative stress, nutrient deprivation, elevated temperature, viral infections, and various acute traumas. Importantly, the HSR and its cardinal members of the heat shock protein 70 family has been shown to protect against a number of degenerative diseases, including severe diseases of the nervous system. The cytoprotective actions of the HSR also include processes involving the lysosomal system, such as cell death, autophagy, and protection against lysosomal membrane permeabilization, and have shown promise in a number of LSDs. This review seeks to describe the emerging understanding of the interplay between these two essential metabolic systems, the lysosomes and the HSR, with a particular focus on their potential as a therapeutic target for LSDs.
Copyright © 2014 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  glycosphingolipids; heat shock proteins; molecular chaperones; sphingolipids; stress response

Mesh:

Substances:

Year:  2014        PMID: 24837749      PMCID: PMC4617124          DOI: 10.1194/jlr.R048090

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  177 in total

1.  Ganglioside GM3 is involved in neuronal cell death.

Authors:  Hosung Sohn; Yong-Sam Kim; Hyun-Taek Kim; Cheol-Hee Kim; Eun-Wie Cho; Hye-Yeon Kang; Nam-Soon Kim; Cheorl-Ho Kim; Seong Eon Ryu; Jeong-Hwa Lee; Jeong Heon Ko
Journal:  FASEB J       Date:  2006-04-24       Impact factor: 5.191

2.  Induction of hsp 72/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes.

Authors:  Y Murakami; Y Uehara; C Yamamoto; H Fukazawa; S Mizuno
Journal:  Exp Cell Res       Date:  1991-08       Impact factor: 3.905

3.  Monitoring autophagy in lysosomal storage disorders.

Authors:  Nina Raben; Lauren Shea; Victoria Hill; Paul Plotz
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

4.  Involvement of heat shock protein-70 in the mechanism of hydrogen peroxide-induced DNA damage: the role of lysosomes and iron.

Authors:  Paschalis-Thomas Doulias; Polychronis Kotoglou; Margarita Tenopoulou; Dimitra Keramisanou; Theodore Tzavaras; Ulf Brunk; Dimitrios Galaris; Charalampos Angelidis
Journal:  Free Radic Biol Med       Date:  2006-11-30       Impact factor: 7.376

5.  Gangliosides enhance apoptosis of thymocytes.

Authors:  J Zhou; H Shao; N R Cox; H J Baker; S J Ewald
Journal:  Cell Immunol       Date:  1998-02-01       Impact factor: 4.868

6.  Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.

Authors:  Chunzhang Yang; Shervin Rahimpour; Jie Lu; Karel Pacak; Barbara Ikejiri; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-31       Impact factor: 11.205

7.  Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator.

Authors:  Elias N Glaros; Woojin Scott Kim; Carmel M Quinn; Jenny Wong; Ingrid Gelissen; Wendy Jessup; Brett Garner
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

Review 8.  Fusogenicity of membranes: the impact of acid sphingomyelinase on innate immune responses.

Authors:  Olaf Utermöhlen; Jasmin Herz; Michael Schramm; Martin Krönke
Journal:  Immunobiology       Date:  2007-12-31       Impact factor: 3.144

9.  Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on 'calpain-cathepsin hypothesis'.

Authors:  T Yamashima; Y Kohda; K Tsuchiya; T Ueno; J Yamashita; T Yoshioka; E Kominami
Journal:  Eur J Neurosci       Date:  1998-05       Impact factor: 3.386

10.  Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.

Authors:  Dairin Kieran; Bernadett Kalmar; James R T Dick; Joanna Riddoch-Contreras; Geoffrey Burnstock; Linda Greensmith
Journal:  Nat Med       Date:  2004-03-21       Impact factor: 53.440

View more
  16 in total

1.  Resveratrol, an activator of SIRT1, improves ER stress by increasing clusterin expression in HepG2 cells.

Authors:  Jinmi Lee; Seok-Woo Hong; Hyemi Kwon; Se Eun Park; Eun-Jung Rhee; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Won-Young Lee
Journal:  Cell Stress Chaperones       Date:  2019-06-10       Impact factor: 3.667

2.  Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.

Authors:  Eugen Mengel; Marc C Patterson; Rosalia M Da Riol; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Paul Harmatz; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Anne Katrine Andreasen; Marie Aavang Geist; Nikolaj Havnsøe Torp Petersen; Linda Ingemann; Thomas Hansen; Thomas Blaettler; Thomas Kirkegaard; Christine Í Dali
Journal:  J Inherit Metab Dis       Date:  2021-09-07       Impact factor: 4.750

Review 3.  Current and Future Treatments for Lysosomal Storage Disorders.

Authors:  David P W Rastall; Andrea Amalfitano
Journal:  Curr Treat Options Neurol       Date:  2017-11-04       Impact factor: 3.598

4.  Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.

Authors:  Thomas Kirkegaard; James Gray; David A Priestman; Kerri-Lee Wallom; Jennifer Atkins; Ole Dines Olsen; Alexander Klein; Svetlana Drndarski; Nikolaj H T Petersen; Linda Ingemann; David A Smith; Lauren Morris; Claus Bornæs; Signe Humle Jørgensen; Ian Williams; Anders Hinsby; Christoph Arenz; David Begley; Marja Jäättelä; Frances M Platt
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

5.  Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.

Authors:  Hui-Yung Song; Huai-Chih Chiang; Wei-Lien Tseng; Ping Wu; Chian-Shiu Chien; Hsin-Bang Leu; Yi-Ping Yang; Mong-Lien Wang; Yuh-Jyh Jong; Chung-Hsuan Chen; Wen-Chung Yu; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2016-12-13       Impact factor: 5.923

6.  Drosophila melanogaster White Mutant w1118 Undergo Retinal Degeneration.

Authors:  María José Ferreiro; Coralia Pérez; Mariana Marchesano; Santiago Ruiz; Angel Caputi; Pedro Aguilera; Rosa Barrio; Rafael Cantera
Journal:  Front Neurosci       Date:  2018-01-04       Impact factor: 4.677

Review 7.  Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises.

Authors:  Fedah E Mohamed; Lihadh Al-Gazali; Fatma Al-Jasmi; Bassam R Ali
Journal:  Front Pharmacol       Date:  2017-07-07       Impact factor: 5.810

Review 8.  Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC.

Authors:  Alberto Benussi; Maria Sofia Cotelli; Alessandro Padovani; Barbara Borroni
Journal:  F1000Res       Date:  2018-02-15

9.  Novel NPC1 mutations with different segregation in two related Greek patients with Niemann-Pick type C disease: molecular study in the extended pedigree and clinical correlations.

Authors:  Evangelia Bountouvi; Anna Papadopoulou; Marie T Vanier; Georgia Nyktari; Spyridon Kanellakis; Helen Michelakakis; Argyrios Dinopoulos
Journal:  BMC Med Genet       Date:  2017-05-04       Impact factor: 2.103

Review 10.  Niemann-Pick type C disease - the tip of the iceberg? A review of neuropsychiatric presentation, diagnosis and treatment.

Authors:  William R H Evans; Chris J Hendriksz
Journal:  BJPsych Bull       Date:  2017-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.